---
title: "Rexulti (brexpiprazole) in major depressive disorder: Clinical trials questions"
description: "Clinical trials questions on Rexulti (brexpiprazole) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Outcome measures, Study results, and Subgroup results. Questions: How were the Rexulti adjunctive depression trials designed? What is the MADRS score used in Rexulti depression trials? How effective is Rexulti added to an antidepressant (Studies 1 and 2)? Is Rexulti 1 mg effective for depression? 4 further questions follow. 8 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole) in major depressive disorder: Clinical trials questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)

Questions that apply to every indication of Rexulti are on [Rexulti (brexpiprazole), all indications](https://www.evicenter.com/medical-information/rexulti).

## Clinical trials

<a id="rexulti-trial-design"></a>

### How were the Rexulti adjunctive depression trials designed?

> “Patients in Study 1 (NCT01360645) were randomized to REXULTI 2 mg once a day or placebo. Patients in 
> Study 2 (NCT01360632) were randomized to REXULTI 1 or 3 mg once a day or placebo. For patients 
> randomized to REXULTI, all patients initiated treatment at 0.5 mg once daily during Week 1. At Week 2, the 
> REXULTI dosage was increased to 1 mg in all treatment groups, and either maintained at 1 mg or increased to 
> 2 mg or 3 mg once daily, based on treatment assignment, from Week 3 onwards. The dosages were then 
> maintained for the 4 remaining weeks.”

Source: [REXULTI: Prescribing information, page 29, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=29)

> “<sup>a</sup>Inclusion criteria for the randomized phase: <50% reduction in HAM-D17 Total Score and ≥14 HAM-D17 score at Week 8 of the prospective phase; <50% reduction in MADRS Total Score and Clinical Global Impression-Improvement Score of ≥3 at each scheduled visit of the prospective phase.<sup>5,6</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Efficacy, captured 2026-11-13](https://www.rexultihcp.com/mdd/efficacy#primary:~:text=criteria%20for%20the%20randomized%20phase%3A,scheduled%20visit%20of%20the%20prospective)

<a id="rexulti-adjunctive-antipsychotic-response"></a>

### Rexulti and adjunctive atypical antipsychotics: what did a class meta-analysis find?

> “In a meta-analysis, response was defined as a 50% improvement from baseline to endpoint on either the MADRS or HAM-D17. Meta-analysis included 17 randomized trials with 3807 patients (duration range: 4-12 weeks) comparing adjunctive antipsychotic treatment to SSRI/SNRI treatment in adult patients (age range: 18-65 years) with MDD. There was a 68% greater odds of response from the antidepressant + adjunctive antipsychotic group vs the placebo + antidepressant group. Discontinuation due to adverse effects were 9.1% in the adjunctive antipsychotic treatment arm vs. 2.6% in the placebo arm.<sup>6</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Partial Response, captured 2026-11-13](https://www.rexultihcp.com/mdd/partial-response#:~:text=In%20a%20meta%2Danalysis%2C%20response%20was,vs.%202.6%25%20in%20the%20placebo)

Note: The partial response page of the Rexulti HCP site cites this meta-analysis as Wen et al., Braz J Med Biol Res, 2014, which pooled trials of adjunctive atypical antipsychotics as a class. The brexpiprazole phase 3 trials that the site cites elsewhere were published in 2015.

## Outcome measures

<a id="rexulti-madrs"></a>

### What is the MADRS score used in Rexulti depression trials?

> “The primary endpoint was change from baseline to Week 6 in the Montgomery-Asberg Depression Rating 
> Scale (MADRS), a 10-item clinician-related scale used to assess the degree of depressive symptomatology, 
> with 0 representing no symptoms and 60 representing worst symptoms.”

Source: [REXULTI: Prescribing information, page 29, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=29)

## Study results

<a id="rexulti-efficacy"></a>

### How effective is Rexulti added to an antidepressant (Studies 1 and 2)?

> “At randomization, the mean MADRS total score was 27. In Studies 1 and 2, REXULTI (plus ADT) 2 mg once 
> daily and 3 mg once daily were superior to placebo plus ADT in reducing mean MADRS total scores.”

Source: [REXULTI: Prescribing information, page 30, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=30)

> “Table 13 
> Change in MADRS from Baseline at Week 6 in Adult Patients for Adjunctive Treatment 
> of MDD (Study 1 and Study 2) 
> Study 
> Treatment Group 
> N 
> Mean Baseline 
> Score (SD) 
> LS Mean Change 
> from Baseline (SE) 
> Placebo-subtracted 
> Difference<sup>*</sup> 
> (95% CI) 
> 1 
> REXULTI (2 mg/day) + ADT<sup>†</sup> 175 
> 26.9 (5.7) 
> -8.4 (0.6) 
> -3.2 (-4.9, -1.5) 
> Placebo + ADT 
> 178 
> 27.3 (5.6) 
> -5.2 (0.6) 
> -- 
> 2 
> REXULTI (1 mg/day) + ADT 
> 211 
> 26.5 (5.6) 
> -7.6 (0.5) 
> -1.3 (-2.7, 0.1) 
> REXULTI (3 mg/day) + ADT 
> 213 
> 26.5 (5.3) 
> -8.3 (0.5) 
> -2.0 (-3.4, -0.5) 
> Placebo + ADT 
> 203 
> 26.5 (5.2) 
> -6.3 (0.5) 
> -- 
> SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval 
> *Difference (drug minus placebo) in least-squares mean change from baseline 
> <sup>†</sup>Dosages statistically significantly superior to placebo”

Source: [REXULTI: Prescribing information, page 30, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=30)

Note: Table 13 lists, for each study and treatment group, N, mean baseline score (SD), LS mean change from baseline (SE), and the placebo-subtracted difference (95% CI).

<a id="rexulti-one-mg-dose"></a>

### Is Rexulti 1 mg effective for depression?

> “The efficacy and safety of REXULTI were also studied in patients randomized to receive 1 mg/day in Study 2 (n=211). Results for the ADT + REXULTI 1 mg group for the primary efficacy parameter were not statistically significant when compared with ADT + placebo.<sup>6</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Efficacy, captured 2026-11-13](https://www.rexultihcp.com/mdd/efficacy#primary:~:text=The%20efficacy%20and%20safety%20of,significant%20when%20compared%20with%20ADT)

> “<sup>c</sup>The 1 mg/day dosage was studied in the trial, but is not recommended for the treatment of MDD.”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Efficacy, captured 2026-11-13](https://www.rexultihcp.com/mdd/efficacy#primary:~:text=1%20mg%2Fday%20dosage%20was%20studied,for%20the%20treatment%20of%20MDD.)

<a id="rexulti-onset"></a>

### When did Rexulti first separate from placebo in depression trials?

> “REXULTI<sup>®</sup> (brexpiprazole) + antidepressant separated from antidepressant + placebo as early as Week 1 and continued to Week 6<sup>1</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=%28brexpiprazole%29%20%2B%20antidepressant%20separated%20from,1%20and%20continued%20to%20Week)

> “The weekly time points prior to Week 6 were not powered for statistical comparison and are descriptive only. Primary endpoint was the mean change from baseline to Week 6 in the MADRS total score in the randomization phase.<sup>1</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=The%20weekly%20time%20points%20prior,total%20score%20in%20the%20randomization)

> “<sup>a</sup>Baseline mean MADRS scores were 27.3 for ADT + placebo (n=178) and 26.9 for ADT + REXULTI (n=175).”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=mean%20MADRS%20scores%20were%2027.3,for%20ADT%20%2B%20REXULTI%20%28n%3D175%29.)

> “<sup>b</sup>P values are based on mixed model repeated-measures analysis.
> <sup>*</sup>P=nominal.”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=values%20are%20based%20on%20mixed%20model%20repeated%2Dmeasures%20analysis.)

> “It is unknown if the differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.<sup>1</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Efficacy, captured 2026-11-13](https://www.rexultihcp.com/mdd/efficacy#primary:~:text=It%20is%20unknown%20if%20the,6%20represent%20clinically%20relevant%20treatment)

Note: The weekly results are from Study 1, as shown on the non-pivotal study data page of the Rexulti HCP site.

## Subgroup results

<a id="rexulti-anxiety-symptoms"></a>

### Does Rexulti work in depression with anxiety symptoms (post hoc analysis)?

> “Using pooled data from 3 similarly designed 6-week randomized studies, including both 2 mg and 3 mg doses, changes were evaluated in MADRS total score in patients with MDD—with and without symptoms of anxiety.<sup>1-3,c,d</sup>
>
> Study limitations: These analyses did not assess the effect of treatment on symptoms of anxiety. Patients with anxiety symptoms had a higher MADRS total score at baseline and the effects of anxiety and illness severity on outcomes were not differentiated. Statistical adjustments were not made for multiple comparisons, potentially inflating the type 1 error rate.<sup>3</sup>
>
> Adding REXULTI reduced mean MADRS total score by over 2 points in patients with MDD with or without symptoms of anxiety<sup>3</sup>:
>
> For patients with symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.19 (95% CI: -3.60 to -0.78)
> For patients without symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.34 (95% CI: -3.58 to -1.10)”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=Using%20pooled%20data%20from%203,%2895%25%20CI%3A%20%2D3.58%20to%20%2D1.10%29)

> “<sup>c</sup>Baseline demographics and clinical characteristics were similar between treatment subgroups; however, patients with symptoms of anxiety were more likely to be female and have a higher MADRS total score at baseline compared with patients without symptoms of anxiety.<sup>3</sup>
>
> <sup>d</sup>Of the patients that received an ADT plus REXULTI 2 mg, 3 mg, or placebo, 49% had symptoms of anxiety, defined as a score of ≥7 at baseline on the HAM-D anxiety/somatization factor.<sup>3</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Non-Pivotal Study Data, captured 2026-11-13](https://www.rexultihcp.com/mdd/non-pivotal-study-data#:~:text=demographics%20and%20clinical%20characteristics%20were,at%20baseline%20on%20the%20HAM%2DD)

<a id="rexulti-subgroups"></a>

### Does Rexulti response differ by age, sex, or race?

> “An examination of population subgroups did not suggest differential response based on age, gender, race, or 
> choice of prospective antidepressant.”

Source: [REXULTI: Prescribing information, page 30, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=30)

## Related pages
- [Medical information: Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/indication)
- [Safety](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/access-and-coverage)
